Rapport Therapeutics accelerates Phase 3 epilepsy trials after data success
Cash position of $490.5M supports pipeline expansion into H2 2029 as Tenacia deal adds $308M milestone potential
Rapport Therapeutics reported fourth-quarter and full-year 2025 financial results on Tuesday, announcing the acceleration of its Phase 3 program for its lead epilepsy drug RAP-219 and securing a strategic partnership that could generate more than $300 million in milestone payments. The biotechnology company, which focuses on developing therapies for neurological disorders, posted a loss per share of $0.72, narrowly beating analyst expectations of a $0.73 loss, according to company filings.
The Boston-based company's net loss widened to $33.8 million in the fourth quarter from $20 million in the year-earlier period, reflecting increased investment in clinical development programs. Despite the deeper losses, investors focused on Rapport's strengthened financial position, with cash, cash equivalents, and short-term investments totaling $490.5 million at the end of 2025. The company projects this runway will fund operations into the second half of 2029, providing substantial flexibility as it advances multiple clinical programs.
The most significant catalyst driving investor interest is the acceleration of RAP-219's Phase 3 program for focal onset seizures, now scheduled to initiate in the second quarter of 2026—moved forward from the third quarter following productive discussions with the U.S. Food and Drug Administration. The accelerated timeline is supported by compelling Phase 2a data released in November 2025, which demonstrated a 77.8% median reduction in clinical seizures with statistical significance (p=0.01). Additionally, 24% of patients achieved seizure freedom over eight weeks, and 72% of patients experienced at least a 50% reduction in seizure frequency.
Rapport also announced expansion of its epilepsy portfolio, adding a planned Phase 3 trial for primary generalized tonic-clonic seizures (PGTCS) in the first half of 2027. The company has already initiated an open-label, long-term safety trial for RAP-219, with initial data expected in the second half of 2026. Additional pipeline updates include ongoing Phase 2 enrollment in bipolar mania, with topline results anticipated in the first half of 2027, and progress on a long-acting injectable formulation of RAP-219, for which investigational new drug-enabling activities will begin in the first quarter of 2026.
In a significant commercial development announced Monday, Rapport formed a strategic collaboration with Tenacia Biotechnology, granting the Chinese company exclusive rights to develop and commercialize RAP-219 in Greater China, including mainland China, Hong Kong, Macau, and Taiwan. Under the terms of the agreement, Rapport received a $20 million upfront payment and is eligible to receive up to $308 million in potential development and commercialization milestones, along with tiered royalties ranging from mid-single digits to mid-teens on net sales in the region. Tenacia will also add Phase 3 clinical trial sites in China, expanding the global footprint of the RAP-219 development program.
Analysts maintain a positive outlook on Rapport, with a consensus rating equivalent to Moderate Buy and an average 12-month price target of approximately $51.20, according to market data. The stock has gained nearly 1% over the past week to trade around $30.54, giving the company a market capitalization of roughly $1.44 billion. Shares have demonstrated significant volatility over the past year, trading within a 52-week range of $7.73 to $42.27, reflecting the binary nature of clinical-stage biotechnology investments.
The epilepsy treatment market represents a multi-billion dollar opportunity, particularly for patients with drug-resistant focal onset seizures who have limited therapeutic options. Rapport's Phase 2a data, which showed robust efficacy in a refractory patient population, positions RAP-219 as a potential best-in-class therapy if Phase 3 results confirm the earlier findings. The company's strategy of simultaneously expanding into additional seizure types while developing novel formulations could significantly broaden the commercial potential of its lead asset.
Looking ahead, investors will focus on the initiation of the Phase 3 program in the second quarter, as well as data readouts from the long-term safety study in the second half of 2026. The company's robust cash position and the Tenacia partnership provide multiple strategic options, including potential expansion of RAP-219 into additional neurological indications or acquisition opportunities to complement its existing pipeline. With operations funded through 2029, Rapport has the financial flexibility to execute on its clinical development plans without immediate dilutive financing pressure.